Premenopausal Osteoporosis

Endocrinol Metab Clin North Am. 2017 Mar;46(1):117-133. doi: 10.1016/j.ecl.2016.09.007. Epub 2016 Nov 24.

Abstract

Most premenopausal women with low trauma fracture(s) or low bone mineral density have a secondary cause of osteoporosis or bone loss. Where possible, treatment of the underlying cause should be the focus of management. Premenopausal women with an ongoing cause of bone loss and those who have had, or continue to have, low trauma fractures may require pharmacologic intervention. Clinical trials provide evidence of benefits of bisphosphonates and teriparatide for bone mineral density in several types of premenopausal osteoporosis, but studies are small and do not provide evidence regarding fracture risk reduction.

Keywords: Osteoporosis treatment; Premenopausal women; Secondary causes of osteoporosis.

Publication types

  • Review

MeSH terms

  • Bone Density Conservation Agents / therapeutic use
  • Bone Density*
  • Diphosphonates / therapeutic use
  • Female
  • Fractures, Bone / etiology
  • Humans
  • Osteoporosis / complications
  • Osteoporosis / drug therapy*
  • Premenopause*
  • Teriparatide / therapeutic use

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Teriparatide